HJC0123

HJC0123 is a novel, potent, and orally active small molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). Developed through fragment-based drug design by researchers at the University of Texas MD Anderson Cancer Center and the University of Texas Medical Branch, HJC0123 targets the STAT3 signaling pathway, which is frequently overexpressed and constitutively active in various malignancies, including ER-negative breast cancer and pancreatic cancer. The compound works by suppressing STAT3 promoter activity, inhibiting STAT3 phosphorylation at the Tyr705 (pY705) site, and reducing total STAT3 protein levels. This leads to cell growth arrest and induction of apoptosis in cancer cells. In preclinical studies, HJC0123 has demonstrated significant efficacy in suppressing the growth of MDA-MB-231 breast xenograft tumors when administered via oral or intraperitoneal routes, showing improved solubility and reduced toxicity compared to earlier lead compounds.